pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1208 |
Genomic Coordinates | chr8: 128150116 - 128150188 |
Synonyms | MIRN1208, hsa-mir-1208, MIR1208 |
Description | Homo sapiens miR-1208 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1208 | |||||||||||||||||||||||||||
Sequence | 12| UCACUGUUCAGACAGGCGGA |31 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Northern | |||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SET | ||||||||||||||||||||
Synonyms | 2PP2A, I2PP2A, IGAAD, IPP2A2, PHAPII, TAF-I, TAF-IBETA | ||||||||||||||||||||
Description | SET nuclear proto-oncogene | ||||||||||||||||||||
Transcript | NM_001122821 | ||||||||||||||||||||
Other Transcripts | NM_003011 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SET | |||||||||||||||||||||
3'UTR of SET (miRNA target sites are highlighted) |
>SET|NM_001122821|3'UTR 1 ATAGAACACTGATGGATTCCAACCTTCCTTTTTTTAAATTTTCTCCAGTCCCTGGGAGCAAGTTGCAGTCTTTTTTTTTT 81 TTTTTTTTTTTTTTCCCTCTTGTGCTCAGTCGCCCTGTTCTTGAGGTCTCTTTTCTCTACTCCATGGTTCTCAATTTATT 161 TGGGGGGAAATACCTTGAGCAGAATACAATGGGAAAAGAGTCTCTACCCCTTTCTGTTCGAAGTTCATTTTTATCCCTTC 241 CTGTCTGAACAAAAACTGTATGGAATCAACACCACCGAGCTCTGTGGGAAAAAAGAAAAACCTGCTCCCTTCGCTCTGCT 321 GGAAGCTGGAGGGTGCTAGGCCCCTGTGTAGTAGTGCATAGAATTCTAGCTTTTTTCCTCCTTTCTCTGTATATTGGGCT 401 CAGAGAGTACACTGTGTCTCTATGTGAATATGGACAGTTAGCATTTACCAACATGTATCTGTCTACTTTCTCTTGTTTAA 481 AAAAAGAAAAAAAAACTTAAAAAAATGGGGTTATAGAAGGTCAGCAAAGGGTGGGTTTGAGATGTTTGGGTGGGTTAAGT 561 GGGCATTTTGACAACATGGCTTCTCCTTTGGCATGTTTAATTGTGATATTTGACAGACATCCTTGCAGTTTAAGATGACA 641 CTTTTAAAATAAATTCTCTCCTAATGATGACTTGAGCCCTGCCACTCAATGGGAGAATCAGCAGAACCTGTAGGATCTTA 721 TTTGGAATTGACATTCTCTATTGTAATTTTGTTCCTGTTTATTTTTAAATTTTCTTTTTGTTTCACTGGAAAGGAAAGAT 801 GATGCTCAGTTTTAAACGTTAAAAGTGTACAAGTTGCTTTGTTACAATAAAACTAAATGTGTACACAAAGGATTTGATGC 881 TTTTCTCTCAGCATAGGTATGCTTACTATGACCTTCCAAGTTTGACTTGTATAACATCACTGTCAAACTTTGTCACCCTA 961 ACTTCGTATTTTTTGATACGCACTTTGCAGGATGACCTCAGGGCTATGTGGATTGAGTAATGGGATTTGAATCAATGTAT 1041 TAATATCTCCATAGCTGGGAAACGTGGGTTCAATTTGCCATTGGTTTCTGAAAGTATTCACATCATTTGGGATACCAGAT 1121 AGCTCAATACTCTCTGAGTACATTGTGCCCTTGATTTTTATCTCCAAGTGGCAGTTTTTAAAATTGGCCTTTTACCTGGA 1201 TATAAATTAATTGTGCCTGCCACCACCATCCAACAGACCTGGTGCTCTAATGCCAAGTTATACACGGGACAGTTGCTGGC 1281 ATGTCTTCATTGGCTATATAAAATGTGGCCAAGAAGATAGGCTCTCAGTAAGAAGTCTGATGGTGAGCAGTAACTGTCCC 1361 TGCTTTCTGGTATAAAGCTCTCAAATGTGACCATGTGAATCTGGGTGGGATAATGGACTCAGCTCTGTCTGCTCAATGCC 1441 ATTGTGCAGAGAAGCACCCTAATGCATAAGCTTTTTAATGCTGTAAAATATAGTCGCTGAAATTAAATGCCACTTTTTCA 1521 GAGGTGAATTAATGGACAGTCTGGTGAACTTCAAAAGCTTTTTGATGTATAAAACTTGATAAATGGAACTATTCCATCAA 1601 TAGGCAAAAGTGTAACAACCTATCTAGATGGATAGTATGTAATTTCTGCACAGGTCTCTGTTTAGTAAATACATCACTGT 1681 ATACCGATCAGGAATCTTGCTCCAATAAAGGAACATAAAGATTTTTTTTGGAAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HEK293 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545212. RNA binding protein: AGO1. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | TZM-bl |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
CLIP-seq Support 1 for dataset GSM545212 | |
---|---|
Method / RBP | PAR-CLIP / AGO1 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000372692.4 | 3UTR | UUCAUUUUUAUCCCUUCCUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
CLIP-seq Support 2 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000372692.4 | 3UTR | CUCUACCCCUUUCUGUUCGAAGUUCAUUUUUAUCCCUUCCUGUCUGAACAAAAACUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
55 hsa-miR-1208 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT076103 | ADORA2B | adenosine A2b receptor | 2 | 2 | ||||||||
MIRT447464 | OSMR | oncostatin M receptor | 2 | 2 | ||||||||
MIRT448145 | ESF1 | ESF1 nucleolar pre-rRNA processing protein homolog | 2 | 2 | ||||||||
MIRT463639 | YY1 | YY1 transcription factor | 2 | 4 | ||||||||
MIRT465065 | TSR1 | TSR1, ribosome maturation factor | 2 | 2 | ||||||||
MIRT468464 | SET | SET nuclear proto-oncogene | 2 | 4 | ||||||||
MIRT480171 | CALM3 | calmodulin 3 | 2 | 2 | ||||||||
MIRT481495 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 2 | 8 | ||||||||
MIRT484111 | ABCD2 | ATP binding cassette subfamily D member 2 | 2 | 4 | ||||||||
MIRT499834 | PCSK9 | proprotein convertase subtilisin/kexin type 9 | 2 | 8 | ||||||||
MIRT500261 | ZNF788 | zinc finger family member 788 | 2 | 6 | ||||||||
MIRT500551 | XBP1P1 | X-box binding protein 1 pseudogene 1 | 2 | 8 | ||||||||
MIRT502697 | CSNK1G1 | casein kinase 1 gamma 1 | 2 | 4 | ||||||||
MIRT517786 | EFCAB11 | EF-hand calcium binding domain 11 | 2 | 2 | ||||||||
MIRT519191 | IVD | isovaleryl-CoA dehydrogenase | 2 | 2 | ||||||||
MIRT523114 | HSPA4L | heat shock protein family A (Hsp70) member 4 like | 2 | 2 | ||||||||
MIRT527425 | NRL | neural retina leucine zipper | 2 | 2 | ||||||||
MIRT529509 | IYD | iodotyrosine deiodinase | 2 | 2 | ||||||||
MIRT533705 | TMEM67 | transmembrane protein 67 | 2 | 2 | ||||||||
MIRT535694 | NEURL1B | neuralized E3 ubiquitin protein ligase 1B | 2 | 2 | ||||||||
MIRT536141 | MAPK14 | mitogen-activated protein kinase 14 | 2 | 2 | ||||||||
MIRT544878 | ZNF543 | zinc finger protein 543 | 2 | 4 | ||||||||
MIRT551362 | EPM2AIP1 | EPM2A interacting protein 1 | 2 | 2 | ||||||||
MIRT555949 | NUCKS1 | nuclear casein kinase and cyclin dependent kinase substrate 1 | 2 | 2 | ||||||||
MIRT561498 | SRSF2 | serine and arginine rich splicing factor 2 | 2 | 2 | ||||||||
MIRT569681 | AMACR | alpha-methylacyl-CoA racemase | 2 | 2 | ||||||||
MIRT572518 | KIAA0232 | KIAA0232 | 2 | 2 | ||||||||
MIRT572877 | OPHN1 | oligophrenin 1 | 2 | 2 | ||||||||
MIRT572924 | PRAMEF1 | PRAME family member 1 | 2 | 2 | ||||||||
MIRT607528 | ABL2 | ABL proto-oncogene 2, non-receptor tyrosine kinase | 2 | 2 | ||||||||
MIRT611076 | ZNF621 | zinc finger protein 621 | 2 | 2 | ||||||||
MIRT613236 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT616542 | NFATC2 | nuclear factor of activated T-cells 2 | 2 | 2 | ||||||||
MIRT620010 | CCDC137 | coiled-coil domain containing 137 | 2 | 2 | ||||||||
MIRT621491 | STYK1 | serine/threonine/tyrosine kinase 1 | 2 | 2 | ||||||||
MIRT622379 | SALL1 | spalt like transcription factor 1 | 2 | 2 | ||||||||
MIRT628226 | FBXL20 | F-box and leucine rich repeat protein 20 | 2 | 2 | ||||||||
MIRT636458 | LRCH3 | leucine rich repeats and calponin homology domain containing 3 | 2 | 2 | ||||||||
MIRT636546 | FAM126B | family with sequence similarity 126 member B | 2 | 2 | ||||||||
MIRT637350 | PIGP | phosphatidylinositol glycan anchor biosynthesis class P | 2 | 2 | ||||||||
MIRT637604 | ZNF554 | zinc finger protein 554 | 2 | 2 | ||||||||
MIRT637732 | EXO5 | exonuclease 5 | 2 | 2 | ||||||||
MIRT638697 | GABRB1 | gamma-aminobutyric acid type A receptor beta1 subunit | 2 | 2 | ||||||||
MIRT640634 | ZIC4 | Zic family member 4 | 2 | 2 | ||||||||
MIRT641535 | SNW1 | SNW domain containing 1 | 2 | 2 | ||||||||
MIRT648796 | VPS8 | VPS8, CORVET complex subunit | 2 | 2 | ||||||||
MIRT663060 | LRIF1 | ligand dependent nuclear receptor interacting factor 1 | 2 | 2 | ||||||||
MIRT666581 | RHOBTB3 | Rho related BTB domain containing 3 | 2 | 2 | ||||||||
MIRT699206 | FYN | FYN proto-oncogene, Src family tyrosine kinase | 2 | 2 | ||||||||
MIRT704875 | CD164 | CD164 molecule | 2 | 2 | ||||||||
MIRT706850 | DNAJB13 | DnaJ heat shock protein family (Hsp40) member B13 | 2 | 2 | ||||||||
MIRT712941 | CCBE1 | collagen and calcium binding EGF domains 1 | 2 | 3 | ||||||||
MIRT714653 | FSTL1 | follistatin like 1 | 2 | 2 | ||||||||
MIRT722320 | SH2D1A | SH2 domain containing 1A | 2 | 2 | ||||||||
MIRT722535 | EPRS | glutamyl-prolyl-tRNA synthetase | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|